EP Patent

EP4684786A3 — Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer

Assigned to Amgen Inc · Expires 2026-04-08 · 0y expired

What this patent protects

Provided herein are KRAS G12C and KRAS G12D inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

USPTO Abstract

Provided herein are KRAS G12C and KRAS G12D inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Drugs covered by this patent

Patent Metadata

Patent number
EP4684786A3
Jurisdiction
EP
Classification
—
Expires
2026-04-08
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.